Evelo Biosciences Inc. [NASDAQ: EVLO] Sees Decrease in Stock Value


Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Evelo Biosciences Inc. shares valued at $8,536 were sold by Bodmer Mark on May 08. At $0.13 per share, Bodmer Mark sold 68,014 shares. The insider’s holdings dropped to 285,128 shares worth approximately $37066.64 following the completion of this transaction.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


Also, McHale Duncan sold 66,730 shares, netting a total of over 8,375 in proceeds. Following the sale of shares at $0.13 each, the insider now holds 97,516 shares.

Before that, Thorell Marella had sold 38,531 shares from its account. In a trade valued at $4,836, the Chief Financial Officer traded Evelo Biosciences Inc. shares for $0.13 each. Upon closing the transaction, the insider’s holdings decreased to 38,531 shares, worth approximately $11890.970000000001.

Analyzing EVLO Stock Performance

On Thursday, Evelo Biosciences Inc. [NASDAQ: EVLO] plunged -2.93% to $0.13. The stock’s lowest price that day was $0.1201, but it reached a high of $0.137 in the same session. During the last five days, there has been a drop of approximately -13.93%. Over the course of the year, Evelo Biosciences Inc. shares have dropped approximately -91.98%. Shares of the company reached a 52-week high of $1.6500 on 01/03/23 and a 52-week low of $0.0243 on 04/27/23. A 50-day SMA is recorded $0.1700, while a 200-day SMA reached $1.3095. Nevertheless, trading volume fell to 0.64 million shares from 0.37 million shares the previous day.

Support And Resistance Levels for Evelo Biosciences Inc. (EVLO)

According to the 24-hour chart, there is a support level at 0.1205, which, if violated, would cause prices to drop to 0.1118. In the upper region, resistance lies at 0.1374. The next price resistance is at 0.1456. RSI (Relative Strength Index) is 39.91 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0045, which suggests the price will decrease in the coming days. Percent R is at 79.64%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is Evelo Biosciences Inc. subject to short interest?

Stocks of Evelo Biosciences Inc. saw a sharp rise in short interest on May 14, 2023 jumping by 1.07 million shares to 3.57 million. Data from Yahoo Finance shows that the short interest on Apr 13, 2023 was 2.5 million shares. A jump of 29.97% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.35 of the overall float, the days-to-cover ratio (short ratio) jumped to 0.35.

Which companies own the most shares of Evelo Biosciences Inc. (EVLO)?

According to Fidelity Management & Research Co filings, the company currently owns 16,197,089 shares, which is about 14.60% of the total EVLO shares outstanding. The investor’s shares have plunged by -231,262 from its previous 13-F filing of 16428351.0 shares. With the completion of the sale transaction, DNCA Finance SA’s stake is now worth $827,973. A total of 0 shares of Evelo Biosciences Inc. were sold by The Vanguard Group, Inc. during the quarter, and -26,195 were sold by BlackRock Fund Advisors. In its current portfolio, Heights Capital Management, Inc. holds 840,577 shares valued at $0.13 million.

In terms of Evelo Biosciences Inc. share price expectations, FactSet research, analysts set an average price target of $1.03 in the next 12 months, up nearly 669.23% from the previous closing price of $0.13. Analysts anticipate Evelo Biosciences Inc. stock to reach $2.00 by 2023, with the lowest price target being $0.10. In spite of this, 4 analysts ranked Evelo Biosciences Inc. stock as a Hold at the end of 2023.


Please enter your comment!
Please enter your name here